Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
BUSINESS
Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
In the face of Keytruda’s (pembrolizumab) increasing dominance in the lung cancer market, Ono Pharmaceutical President Gyo Sagara says his company has a three-pronged recipe to have Opdivo (nivolumab) regain ground in the PD-1 inhibitor space, with one being label…
To read the full story
Related Article
- Ono’s Drug Sales Skid in Q1, but Opdivo Royalties Underpin Earnings
August 2, 2019
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
- Opdivo Sales Up 15% in April-June: Ono
August 2, 2018
- Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
May 11, 2018
BUSINESS
- Medipal, JCR Kick Off Japan PI/II of MPS IIIB Therapy
December 4, 2024
- Ono Teams Up with Canada’s Congruence in Cancer Drug Discovery
December 4, 2024
- Australia Accepts Shionogi’s NDA for Antibiotic Cefiderocol
December 4, 2024
- Forxiga Crowned in HP Market Promotion Ranking in October: Intage
December 4, 2024
- GE HealthCare to Fully Acquire Nihon Medi-Physics Next Year
December 3, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…